eLife
(Aug 2022)
How splicing confers treatment resistance in prostate cancer
Prathyusha Konda,
Srinivas R Viswanathan
Affiliations
Prathyusha Konda
ORCiD
Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
Srinivas R Viswanathan
ORCiD
Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
DOI
https://doi.org/10.7554/eLife.82070
Journal volume & issue
Vol. 11
Abstract
Read online
A splice variant of the androgen receptor that drives prostate cancer resistance translocates into the nucleus using a different mechanism from the full-length receptor and exhibits distinct molecular properties once inside.
Keywords
Published in eLife
ISSN
2050-084X (Online)
Publisher
eLife Sciences Publications Ltd
Country of publisher
United Kingdom
LCC subjects
Medicine
Science: Biology (General)
Website
https://elifesciences.org
About the journal
WeChat QR code
Close